Wild Horseshoe Crab Welfare and Biomedical Use

Horseshoe crabs are harvested for their unique blood used in pharmaceutical testing; the welfare implications of bleeding and release have growing scientific attention.

Key Facts

Limulus Amebocyte Lysate (LAL) derived from horseshoe crab blood is used globally to test medical devices and drugs for bacterial contamination.
An estimated 500,000 horseshoe crabs are bled annually in the US for biomedical purposes.
Mortality rates from bleeding are disputed — estimates range from 3% to 30% of bled animals.
A synthetic alternative (recombinant Factor C, rFC) has been developed and validated in some markets.
Horseshoe crabs spawn in vast numbers on beaches in spring; their eggs are critical food for migratory shorebirds.

Welfare Considerations

The welfare of horseshoe crabs during and after biomedical bleeding involves capture stress, transport, the bleeding procedure itself (up to 30% of blood volume removed), and return to sea. Bled animals show changes in behaviour, immune function, and mating activity compared with unbled controls. Mortality from the process, while disputed in magnitude, represents a real welfare cost. The ecological importance of horseshoe crab spawning — supporting entire shorebird migration systems — means their welfare is entangled with the welfare of thousands of other species. Adoption of rFC as a replacement for LAL would eliminate this welfare concern entirely.

What You Can Do

Support campaigns advocating for pharmaceutical industry adoption of synthetic rFC over horseshoe crab LAL.
Raise awareness of horseshoe crab welfare as a medical supply chain animal welfare issue.
Support conservation efforts protecting horseshoe crab spawning beaches from development and harvest.
Encourage pharmaceutical companies you use to disclose their LAL vs. rFC sourcing policies.